Related coverage linked through entity extraction aliases.
Jul 15, 2026
Lund University and Skåne University Hospital have developed a collaborative model to accelerate cell and gene therapy delivery by integrating academia, healthcare, and innovation from the start. The approach includes the Cell and Gene Therapy Navigator, a tool to track technical, clinical, and commercial progress simultaneously, aiming to prevent promising therapies from being lost in the translational gap.
Apr 01, 2026
Johnson & Johnson invests over $1 billion in a new Pennsylvania cell therapy manufacturing facility for cancer and neurological diseases. The expansion addresses growing demand for advanced therapies while highlighting workforce training challenges in GMP environments. Other developments include new cell line technology for viral vector production and CRISPR-edited CAR-T manufacturing partnerships.
Mar 03, 2026
University of Melbourne receives $2.1 million for quantum-enabled brain-on-chip platform for neurological diseases, while Evogene partners with Queensland University of Technology on AI-driven cancer therapeutics targeting chemotherapy resistance.
Mar 03, 2026
Johnson & Johnson announced a $1 billion cell therapy manufacturing facility in Pennsylvania while reportedly exploring a sale of its DePuy Synthes orthopedics business for over $20 billion.
Mar 02, 2026
The global drug discovery services market is valued at $22.04 billion in 2025 and is forecast to reach $75.13 billion by 2034, growing at a 14.6% CAGR from 2026-2034, driven by rising industry demand and technological advancements.
Feb 20, 2026
Johnson & Johnson announced a more than $1 billion investment to build a new cell therapy manufacturing facility in Lower Gwynedd, Pennsylvania, creating 500 skilled biomanufacturing jobs and 4,000 construction jobs as part of its $55 billion U.S. investment strategy through early 2029.
Feb 19, 2026
Johnson & Johnson announced plans to invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, expected to create 500 jobs when fully operational in 2031.
Feb 18, 2026
Johnson & Johnson announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, part of the company's $55 billion U.S. investment strategy through early 2029.
Feb 18, 2026
Johnson & Johnson announced plans to invest over $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, creating 500 biomanufacturing jobs as part of its $55 billion U.S. expansion commitment through 2029.
